This reference antibody, based on brazikumab, is utilized in bioanalytical assays and research for drug development and biosimilar studies. It targets interleukin-23 (IL-23), a key cytokine in chronic inflammation associated with autoimmune diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel disease (including Crohn’s disease). By neutralizing IL-23, it inhibits immune overactivity, reducing inflammation. Originally developed as a therapeutic candidate for these conditions, it now serves as a critical reference standard to evaluate the efficacy, specificity, and binding of novel anti-IL-23 antibodies in pharmaceutical research and quality control.